復星醫藥(02196.HK)擬7.5億人民幣收購同業97.82%

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

復星醫藥(02196.HK)擬7.5億人民幣收購同業97.82%

阿思達克 06-26 05:25

復星醫藥(02196.HK)公布，附屬奧鴻藥業擬參與競購成都力思特製藥75.9085%股權，涉及5,475.28萬股股份，對價不超過5.9億人民幣。同時，向力思特製藥股東收購21.9166%股權，涉及1,580.84萬股股份，代價約1.57億人民幣。

完成後，奧鴻藥業共計持有力思特製藥97.8251%股權，後者主要產品鹽酸戊乙奎醚注射液(長托寧)主要應用於手術麻醉術前用藥，與奧鴻藥業現有產品的主要應用科室具有較好的協同性。

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

復星醫藥(02196.HK)擬7.5億人民幣收購同業97.82%

Services

About Us

Agreement Statement